Other Information .
−Removed: Conformed version of the Company’s Articles of Incorporation,
−Removed: as amended by that Certificate of Amendment previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K on
−Removed: November 8, 2019.
+Added: Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc.
+Added: and Silver Rock Associates, Inc., dated May 4, 2020
Filed herewith
−Removed: Share Subscription Agreement between the Company and the Investor dated January 17, 2020.
−Removed: Incorporated by reference to the designated exhibit of the Company’s
−Removed: Current Report on Form 8-K filed on January 21, 2020.
+Added: Amendment No.
+Added: 1 to Right of First Refusal Agreement by and between PharmaCyte Biotech, Inc.
+Added: and Silver Rock Associates, Inc., dated July 15, 2020
+Added: Filed herewith
Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
8 unchanged sentences
Filed herewith
−Removed: Interactive Data Files for the Company’s Form 10-Q for the period ended January 31, 2020
+Added: Interactive Data Files for the Company’s Form 10-Q for the period ended July 31, 2020
Submitted herewith.
−Removed: * This exhibit is being filed pursuant to Item 601(b)(3)(i) of Regulation
−Removed: S-K which requires a conformed version of the Company’s Articles of Incorporation, as amended, reflecting all amendments
−Removed: in one document.
Pursuant to the requirements of the Securities
2 unchanged sentences
PharmaCyte Biotech, Inc.
−Removed: March 13, 2020
+Added: September 11, 2020
/s/ Kenneth L.
1 unchanged sentence
(Duly Authorized Officer and Principal Executive Officer)
−Removed: March 13, 2020
+Added: September 11, 2020
/s/ Carlos A.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.